Angiocrine Bioscience, Inc. is a clinical-stage biotechnology company developing Advanced Reparative Medicines consisting of engineered human endothelial cells (E-CEL cells). Angiocrine utilizes its proprietary E-CEL Platform to create multiple versions of E-CEL cells to repair damaged tissues and organs and to treat serious medical conditions.